---
title: "Correction: Santen Pharmaceutical Logs 15% Lower Core Net Attributable Profit for Nine Months to December 2024"
date: "2025-02-08 03:11:24"
summary: "(Corrects the fourth paragraph to indicate that the dividend forecast for the fiscal year ending March. 31 was revised to 36 yen per share; also corrects the third paragraph to indicate that the previous revenue was 222.83 billion yen)Santen Pharmaceutical recorded a core net profit attributable to owners of 33.8..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

(Corrects the fourth paragraph to indicate that the dividend forecast for the fiscal year ending March. 31 was revised to 36 yen per share; also corrects the third paragraph to indicate that the previous revenue was 222.83 billion yen)

Santen Pharmaceutical recorded a core net profit attributable to owners of 33.8 billion yen for the nine months ended Dec. 31, 2024, 15% lower than 39.6 billion yen logged for the same period a year ago.

The company's earnings per share for the reporting period decreased to 96.02 yen from 107.29 yen per share a year ago, according to a Thursday filing with the Tokyo Exchange.

Revenue of the pharmaceutical company came in at 222.77 billion yen, slightly lower than 222.83 billion yen logged a year earlier.

The company forecast a core net profit of 41.3 billion yen, a basic EPS of 117.05 yen, and revenue of 302.0 billion yen. It also revised its dividend forecast for the fiscal year ending March. 31 to a final dividend of 36 yen per share.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250207:G2465234:0/)
